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Evolution of melanoma from a primary tumor to widespread metastasis is crucially 
dependent on lymphatic spread. The mechanisms regulating the initial step in met-
astatic dissemination via regional lymph nodes remain largely unknown; however, 
evidence supporting the establishment of a pre-metastatic niche is evolving. We have 
previously described a dysfunctional immune profile including reduced expression of 
dendritic cell (DC) maturation markers in the first node draining from the primary tumor, 
the sentinel lymph node (SLN). Importantly, this phenotype is present prior to evidence 
of nodal metastasis. Herein, we evaluate melanoma-derived extracellular vesicles 
(EVs) as potential mediators of the premetastatic niche through cargo-specific polar-
ization of DCs. DCs matured in vitro in the presence of melanoma EVs demonstrated 
significantly impaired expression of CD83 and CD86 as well as decreased expression 
of Th1 polarizing chemokines Flt3L and IL15 and migration chemokines MIP-1α and 
MIP-1β compared to liposome-treated DCs. Profiling of melanoma EV cargo identified 
shared proteomic and RNA signatures including S100A8 and S100A9 protein cargo, 
which in vitro compromised DC maturation similar to melanoma EVs. Early evidence 
demonstrates that similar EVs can be isolated from human afferent lymphatic fluid 
ex vivo. Taken together, here, we propose melanoma EV cargo as a mechanism by 
which DC maturation is compromised warranting further study to consider this as a 
potential mechanism enabled by the primary tumor to establish the premetastatic 
niche in tumor-draining SLNs of patients.
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inTrODUcTiOn
Regional lymph node metastasis remains among the most predictive prognostic markers for 
patients with solid tumors (1). Numerous studies in melanoma have demonstrated that the pres-
ence and number of metastatic lymph nodes directly correlate with decreased overall survival in 
patients presenting with clinical stages II (no lymph node metastases) and III (positive lymph node 
Abbreviations: EVs, extracellular vesicles; SLN, sentinel lymph node; DC, dendritic cell.
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metastases) (2). As the treatment recommendations and prog-
nosis is critically determined by lymph node status, lymphatic 
mapping and biopsy of the first tumor-draining lymph node or 
sentinel lymph node (SLN) has been adopted as the standard 
of care for clinical stage IB and II cutaneous melanoma (2). Its 
acceptance subsequently led investigators to better define the 
benefit of sentinel lymph node biopsy (SLNB) (3). To address 
this, the Multicenter Selective Lymphadenectomy Trial I was 
conducted as a randomized phase III clinical trial, which 
demonstrated in a cohort of 2001 patients with intermediate 
thickness melanoma, that SLNB prolongs disease-free survival 
for all patients and significantly improves melanoma-specific 
survival for node-positive patients (4). While the value of iden-
tifying SLN-positive disease has been evaluated clinically, the 
immunological changes underlying the tumor permissiveness of 
the SLN remains poorly characterized.
The epicenter of the adaptive immune response, the lymph 
node, anatomically localizes antigen-presenting dendritic cells 
(DCs) in proximity to antigen-specific lymphocytes to orches-
trate effective responses between the detection and effector arms 
of immunity (5). In the tumor setting, tumor-draining SLNs also 
serve as the initial site of solid tumor (melanoma) metastases (6). 
In order for even microscopic metastases to harbor in seemingly 
immune-competent SLNs, changes to the lymphoid microenvi-
ronment are believed to be required (7). Initially described in 
Paget’s “seed and soil” hypothesis, our understanding of how 
tumor cells (the “seed”) prepare the microenvironment (the 
“soil”) for metastasis has relied predominantly on the role of 
tumor cells as drivers of metastasis (8). To define the lymphatic 
“soil” of regional lymph nodes in patients with melanoma, previ-
ous work in our laboratory utilized immunohistochemical (IHC) 
techniques to define the regional immune profile of SLNs with 
or without nodal metastasis compared to healthy control lymph 
nodes. Features including helper T cell polarization toward 
Th2, decreased expression of dendritic cell (DC) costimulatory 
marker CD86, and decreased CD8+ T cells differentiated mela-
noma SLNs from control lymph nodes obtained from patients 
undergoing prophylactic mastectomy (9). Notably, these changes 
in the SLN immune profile were independent of the presence 
of metastatic melanocytes. These initial findings in T  cells 
were further evaluated in fresh lymphatic (SLN) tissue by flow 
cytometry techniques suggesting the existence of a premetastatic 
niche precedes clinically evident metastases in the SLN micro-
environment (10); however, the mechanisms responsible for the 
effects on the monocytic lineage in the SLN remain unexplored. 
Taken together, increasing evidence suggests that while tumor 
cells actively contribute to the chronic repolarization of their 
metastatic microenvironments, the initial events responsible 
for permitting early (first metastatic cell) regional metastasis 
precedes even tumor cells.
Within the lymph node, DCs are the predominant antigen-
presenting cells responsible for detecting and presenting 
tumor-associated antigens to lymphocytes (5). Matured from 
the monocyte lineage, DC maturation is tightly regulated by 
the requirement of three sequential signals including (1) MHC 
expression for antigen presentation (2); expression of costimu-
latory/maturation markers CD80 (B7-1), CD83, and CD86 
(B7-2) that bind receptors on stimulated effector lymphocytes; 
and (3) cytokine production to modulate the ultimate nature of the 
effector immune response (11). Beyond these canonical signals, 
DC subsets can be further classified by differential expression 
of various receptors including DC1 and DC2 polarizing surface 
receptors CD11c and CD123, respectively (12). Taken together, 
these phenotypic markers in conjunction with the surrounding 
cytokine and chemokine milieu provide critical insight regarding 
the functions of DCs downstream.
Recently, extracellular vesicles (EVs) have emerged as media-
tors of a novel mechanism of intercellular communication (13). 
Secreted from nearly all cell types, membrane-bound EVs are 
composed of lipid, protein, and nucleic acid contents derived 
from the parent cell. Unlike soluble factors that are often limited 
in eliciting their effects in close proximity to their cell of origin, 
EVs have the unique capacity to transfer their contents to target 
cells across both paracrine and endocrine distances (14). Within 
the context of immune regulation, EVs have demonstrated 
various functions in modulating immune responses in vitro and 
in vivo (13). Originating from immune cells, EVs drive immune 
activation through direct antigen presentation to T and B cells 
(15, 16), indirect antigen presentation through antigen transfer to 
DCs (17), and activation of natural killer (NK) cells (18) and mac-
rophages (19). In contrast, EVs originating from tumor cells have 
demonstrated immune inhibitory functions including decreased 
NK and CD8+ T cell cytotoxicity (20) and promotion of regula-
tory T cells (21) and myeloid-derived suppressor cells (MDSCs) 
(22). Recently, tumor-derived EVs have also demonstrated the 
capacity to inhibit DC maturation from the monocyte lineage 
(23); however, the mechanisms regulating this process have 
not been elucidated. In this study, we evaluate hypoxia-induced 
human melanoma-derived EVs for their role in regulating DC 
maturation in a cargo-dependent manner.
MaTerials anD MeThODs
Patient samples
Informed consent was obtained from all subjects participating 
in the following studies, following study approval by the Mayo 
Clinic Institutional Review Board.
Peripheral Blood
Peripheral blood from anonymous healthy donors was collected 
as clinical residual and peripheral blood mononuclear cells 
(PBMCs) isolated by Ficoll gradient.
Lymph Node Tissue
Fresh lymphatic tissue was collected as previously described 
(10). Briefly, lymph node specimens and proximal afferent 
lymphatic channels were obtained from patients with melanoma 
undergoing lymphatic mapping and SLNB as a standard of care 
(melanoma cohort). Control lymph nodes were obtained from 
women undergoing prophylactic mastectomy with no evidence 
of cancer (healthy control cohort). Following lymph node 
collection and initial pathology review, two non-contiguous 
1-mm shavings were submitted for this research study, and 
the remainder of the frozen tissue was reviewed per routine 
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clinical practice. Intact and clamped afferent lymphatic channels 
were dissected from the SLN following SLNB in the melanoma 
cohort. Research specimens were transported in RPMI media 
and lymph nodes processed into a single-cell suspension 
using Miltenyi gentleMACs Dissociator (Miltenyi Biotech, 
Bergisch Gladbach, Germany) according to the manufacturer’s 
instructions.
cyTOF analysis of slns
Briefly, single-cell suspensions of fresh SLN tissue was cultured 
overnight at 37°C in RPMI media (Corning) supplemented 
with 10% FBS (Millipore) and 1% penicillin, streptomycin, 
and glutamine (PSG) in the presence of 20  IU/mL IL-2 
(Prometheus). Following incubation, cells were labeled with 
viability cisplatin (Cell-ID, Fluidigm) for dead cell exclusion 
and washed in MaxPar cell staining buffer (Fluidigm). Cells 
were subsequently fixed in 1.6% paraformaldehyde, blocked 
with anti-Fc receptor antibodies, and labeled with antibod-
ies to cell surface markers including CD11a (142Nd), ICOS 
(143Nd), CD8a (146Nd), CD11c (147Sm), PDL1 (148Nd), 
HLA-DR/DP (150Nd), CD123 (151Eu), Tim-3 (153Eu), CD3 
(154Sm), CD86 (156Gd), CCR7 (159Tb), CD14 (160Gd), 
CD80 (162Dy), Lag-3 (165Ho), CD25 (168  Tm), CTLA-4 
(170Er), CD20 (171Yb), CD4 (174Yb), PD-1 (175Lu), CD56 
(176Yb), and CD16 (209Bi). Following 30-min incubation with 
metal-conjugated antibodies, cells were washed and permea-
bilized in methanol prior to intracellular staining with T-bet 
(161Dy), Galectin-9 (163Dy), GATA3 (167Er), and Granzyme 
B (173Yb). After 30-min incubation, cells were again washed 
and labeled with intercalation solution (Iridium) for resolution 
of single-cell events. Stained cells were washed, resuspended 
in water containing calibration beads, and analyzed by CyTOF 
instrument (Fluidigm). High-dimensional single-cell analysis 
was conducted by viSNE analysis (Cytobank) sampling 25,000 
cellular events/SLN using clustering channels CD3, CD4, CD8, 
CD20, CD56, CD14, and HLA-DR.
cell lines
Human melanoma cell lines SKMEL28 (HTB-72), A375 (CRL-
1619), and C32TG (CRL-1579), and normal, primary adult 
epidermal melanocytes (PCS-200-013) were purchased directly 
from American Type Culture Collection (ATCC), and all cell 
lines were passaged fewer than 10 times prior to storage to pre-
serve authenticity. SKMEL28 and C32TG cells were cultured in 
Minimum Essential Media supplemented with 1% non-essential 
amino acids and A375 cells cultured in Dulbecco’s Modified Eagle 
Medium (Corning). All melanoma cell lines were additionally 
supplemented with 10% exosome-free FBS (Systems Bioscience) 
and 1% PSG (Corning) and cultured at 37°C and 5% CO2. 
Primary epidermal melanocytes were cultured with dermal cell 
basal medium supplemented with adult melanocyte growth kit 
according to the manufacturer’s instructions (ATCC). Routine 
screening of Mycoplasma contamination was conducted with 
MycoProbe Mycoplasma Detection Assay (R&D Systems) most 
recently in September 2016. All cell lines measured with negative 
OD values of <0.05.
hypoxic cell culture
For hypoxia induction, Petaka G3 low oxygen transfer flasks 
(Neuromics) were used to culture melanoma cell lines or primary 
melanocytes for 48–96 h at 37°C until >80% confluent.
eV isolation and Quantification
For EV quantification and coculture experiments, EVs were iso-
lated from cell culture supernatant using Total Exosome Isolation 
Reagent (ThermoFisher) according to the manufacturer’s instruc-
tions (reagent isolation). For RNA characterization, recombinant 
protein experiments, and electron microscopy (EM) visualiza-
tion, conditioned media or lymphatic fluid was prefiltered with 
a 0.8-µm Minisart NML syringe filter (Sartorius), and EVs were 
isolated on membrane-affinity spin columns by exoEasy maxi kit 
(Qiagen) according to the manufacturer’s instructions (column 
isolation). Unloaded liposomes (Sigma) were resuspended and 
sonicated for 30 s to be of similar size distribution and concentra-
tion for use as a negative control. To quantify total particle con-
centration and size distribution, nanoparticle tracking analysis 
(NTA) was performed with NanoSight NS300 (Malvern, UK). 
Vesicle preparations were diluted 1:100 (reagent isolation) or 
1:1000 (column isolation) in HPLC-grade water and loaded into 
the sample chamber with sterile 1-mL syringe and visualized 
with NTA 2.3 software. Three video captures of 30 s each were 
taken of each vesicle preparation and particle concentration and 
size distribution calculated utilizing manual shutter and gain 
adjustments. Following analysis by the software, vesicle size was 
reported as mean particle size ± SEM and particle concentration 
as total concentration ± SEM.
immunogold labeling and negative 
staining
Isolated EVs were concentrated by ultrafiltration on 100-K 
filters (Millipore), adhered to carbon-coated 200 mesh Cu 
grids, and labeled with CD63 antibody (BD Biosciences). 
Grids were incubated with secondary 10 nm gold-conjugated 
antibody with matching isotypes. Following a wash in 0.1  M 
phosphate buffer, pH 7.0, grids were fixed with 4% paraform-
aldehyde +  1% glutaraldehyde and negative stained with 1% 
phosphotungstic acid. Micrographs were acquired using a 
JEOL1400 Plus transmission electron microscope operating at 
80 kV (Peabody, MA, USA).
Transmission electron Microscopy
Segments of lymphatic channel (2–4 mm in length) were fixed 
in 4% paraformaldehyde with 1% glutaraldehyde in phosphate-
buffered saline, pH 7.2. Following fixation, channels were 
processed with the use of a laboratory microwave oven (Pelco 
BioWave 3450, Ted Pella, Inc., Redding, CA, USA). Briefly, 
tissue was secondarily fixed with 1% osmium tetroxide and 2% 
uranyl acetate, dehydrated through a graded ethanol series, and 
embedded into Embed 812 resin. Following a 24-h polymeriza-
tion at 60°C, 0.1-µm ultrathin sections were poststained with 
lead citrate. Micrographs were acquired using a JEOL1400 Plus 
transmission electron microscope operating at 80 kV (Peabody, 
MA, USA).
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In Vitro Dc culture
CD14+ monocytes were negatively selected (Miltenyi Biotech) 
from the PBMCs of healthy human donors. Monocytes were 
cultured with 10  ng/mL GM-CSF (Genzyme) and 1  ng/mL 
IL-4 (R&D Systems) for 5 days and matured with 100 ng/mL 
CD40L (R&D Systems) for 2 days. Differentiating monocytes 
were cocultured with SKMEL28-derived EVs or liposomes 
(1 ×  1010  particles/mL) from day 0, or recombinant proteins 
S100A8 (Abcam), S100A9 (ThermoFischer), Annexin A1 
(R&D Systems), and/or ICAM1 (R&D Systems) at 10  µg/mL 
from day 5.
Flow cytometry and imagestream
Dendritic cell surface markers were assessed by flow cytom-
etry on Day 7 using surface markers CD14, CD11c, CD123, 
HLA-DR, HLA-ABC, CD83, AND CD86 (BD Pharmingen). 
Statistical significance was determined using two-tailed t-tests 
(p < 0.05). For imaging flow cytometry, prior to coculture with 
DCs, melanoma-derived EVs were isolated and fluorescently 
stained with general lipid membrane marker PKH67 (Sigma) 
according to the manufacturer’s instructions. Briefly, 2 µL of 
PKH was diluted in 0.5  mL Diluent C and then mixed with 
EV preparation for 4  min. Following the incubation, 1  mL 
complete culture media was added, and EVs were washed 
and concentrated over 100-K ultrafilters (Millipore). After 
7-day coculture, DCs were analyzed using ImageStream MKII 
imaging flow cytometer (Amnis) and analyzed using Ideas 6.2 
software (Amnis).
cytokine and chemokine Multiplex
Cytokine and chemokine protein concentrations were measured 
in cell culture supernatants using the MagPlex Milliplex human 
38-analyte multiplex panel (Millipore) per the manufacturer’s 
instructions and as described (24). The analytes measured include 
EGF, FGF-2, eotaxin, TGF-α, G-CSF, Flt3L, GM-CSF, fractalkine, 
IFNα2, IFN-γ, GRO, IL-10, MCP-3, IL-12p40, MCD, IL-12p70, 
IL-13, IL-15, sCD40L, IL-17A, IL-1RA, IL-1α, IL-9, IL-1β, IL-2, 
IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, 
TNF-α, TNF-β, and VEGF. Assay was read by Luminex xPONENT 
technology (Luminex, Austin, TX, USA). Analyte concentrations 
were quantified using a standard curve with a range of 1.6 and 
5,000  pg/mL, using Milliplex Analyst software (VigeneTech, 
Carlisle, MA, USA). All samples were run in duplicate and aver-
aged to determine concentration.
eV Proteomics
Extracellular vesicles were cultured under hypoxic and reduced 
serum conditions. For hypoxia induction, Petaka G3 low oxygen 
transfer flasks (Neuromics) were used to culture melanoma cell 
lines for 48 h at 37°C until >80% confluent. Purified EVs were 
then lysed, and protein content was measured by BCA assay 
and run on 4–20% TGX Ready gel (Bo-Rad). Protein bands 
were visualized by silver stain technique, according to the 
manufacturer’s instructions (ThermoFisher). Silver-stained gel 
sections were prepared for MS analysis as previously described 
(25). Briefly, gel fractions were destained in 15 mM potassium 
ferricyanide:50  mM sodium dithionite:H2O solution, reduced, 
and alkylated with 50  mM TCEP and 20  mM idoacetamide 
for 2  h in the dark. Acetonitrile-dehydrated gel sections were 
digested in 5 ng/µL trypsin overnight at 37°C. Peptides were then 
extracted in 2% TFA followed by acetonitrile, and both extract 
solutions combined, dried, and stored at −80°C. LC-MS/MS 
analysis was conducted on either a Thermo Scientific Orbitrap 
Elite Hybrid Mass Spectrometer or QExactivePlus (Thermo 
Fisher Scientific, Bremen, Germany) both coupled to a Thermo 
Ultimate 3000 RSLCnano HPLC systems, using handpacked 
Magic C18 3  μm: 25  cm ×  75-μm columns at ambient tem-
peratures and Magic C18 5 μm trap at a flow rate of 325  nL/
min. The Orbitrap Elite mass spectrometer experiment was set to 
perform a FT full scan from 340–1,500 m/z with resolution set 
at 120,000 (at 400 m/z), followed by linear ion trap rapid CID 
MS/MS scans on the top 25 ions. The QExactivePlus experiment 
performed a FT full scan from 340–1,500 m/z with resolution at 
70,000 and HCD on the 20 ions at 17,500. Tandem mass spectra 
were extracted by MSConvert, and all MS/MS samples were 
analyzed using Mascot (Matrix Science, London, UK; version 
2.4.0) and X! Tandem (The GPM, http://thegpm.org; version 
X! Tandem Sledgehammer (2013.09.01.1)) set up to search the 
Swissprot all species database (Nov2014, 1,093,672 entries) with 
reverse decoy sequences. Both searches assumed the digestion 
enzyme trypsin and a parent ion tolerance of 10.0  PPM with 
fragment ion mass tolerance of 0.60 Da for the Elite or 0.02 Da 
for the QXactive Plus raw files. Oxidation of methionine and 
the iodoacetamide derivative of cysteine were specified as vari-
able modifications. Scaffold (version Scaffold_4.6.2, Proteome 
Software Inc., Portland, OR, USA) was used to validate MS/
MS-based peptide and protein identifications. Peptide identi-
fications were accepted if they could be established at greater 
than 95.0% probability by the Scaffold Local FDR algorithm 
or the Peptide Prophet algorithm (26) and contained at least 
two identified peptides. Protein probabilities were assigned by 
the Protein Prophet  algorithm (27). The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository with the data set 
identifier PXD005539. Protein identifications matched across all 
three melanoma cell line EV preparations (SKMEL28, C32TG, 
A375) were reported, as well as EV specific proteins and intracel-
lular proteins present in non-EV cellular compartments for EV 
characterization.
real-time rT-Pcr
Isolated EVs were eluted from column with QIAzol lysis buffer 
and RNA isolated by exoRNeasy kit (Qiagen) following the 
manufacturer’s instructions. RNA content was quantified by 
spectrophotometer DS-11 (DeNovix), and equal concentrations 
of each EV RNA preparation were then converted to cDNA with 
RT2 First Strand Kit (Qiagen). The cDNA was mixed with RT2 
SYBR Green Mastermix before loading in a 96-well array contain-
ing genes specific to the Th1 and Th2 pathways (Qiagen). The 
reactions were read by real-time cycler (ABI ViiA7), and fold 
regulation was calculated for each gene using RT2 Profiler PCR 
Array Data Analysis software.
FigUre 1 | illustration of altered regional immune profile signatures preceding clinical evidence of nodal metastasis. Mass cytometry of 25 analytes 
was performed on single-cell suspensions of premetastatic SLN and healthy lymph node. Illustrative images of viSNE analysis plots of broad immune cell surface 
markers in melanoma and control SLNs (a). Global differences in surface markers HLA-DR, CD80, and CD86 and transcription factors T-bet and GATA3 were 
similarly compared. Decreased CD80 and T-bet expression was observed in premetastatic SLN compared to control lymph node (B). On viSNE plot each cell is 
depicted as a single dot on the plot, and marker expression is indicated by color intensity.
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resUlTs
To complement our previous IHC work assessing changes in the 
immune cell composition of human SLNs prior to metastasis, we 
performed deep phenotyping of multiple immune cell param-
eters using mass cytometry on freshly isolated SLN tissue. In 
this pilot analysis, fresh lymph node tissue was obtained from a 
patient with melanoma undergoing SLNB (clinically negative for 
metastatic disease) compared to a healthy lymph node obtained 
from a patient undergoing prophylactic mastectomy procedure. 
Utilizing a 25 analyte panel, differences in a variety of immune 
cell subsets could be assessed simultaneously. No differences 
were observed in the overall distribution of broad immune cell 
subsets including T cells (CD4+ and CD8+), B cells (CD20+), 
monocytes (CD14+), and NK cells (CD56+) when comparing 
premetastatic melanoma to control lymph nodes (Figure 1A). 
However, an overall decrease in DC costimulatory marker 
CD80 and Th1 polarizing transcription factor T-bet expression 
was observed in the premetastatic SLN compared to the healthy 
node (Figure  1B). This illustration coincides with the earlier 
IHC studies, which showed a statistically significant decrease in 
DC maturation marker CD86 and a decrease in CD8+ T cells 
and an overall shift from Th1 to Th2 polarization (9). Additional 
studies by Grotz et  al. further characterized the loss of CD8+ 
T cells in the SLN prior to metastasis (10); however, mechanisms 
exploring the compromised DC maturation phenotype were not 
elucidated. Therefore, we chose to develop an in vitro model in 
this study to evaluate the effects of melanoma-derived EVs on 
DC maturation.
As melanoma penetrates the layers of the dermis to gain 
access to the draining lymphatics, a hypoxic core develops in 
which selective pressures encourage evolution of transformed 
cells and induce secretion of angiogenic factors responsible for 
initiating neovascularization (28). Thus, we sought to evaluate the 
effects of hypoxic stress on EV production in human malignant 
melanocytes in vitro. Following hypoxic culture, EVs (including 
both exosome and microvesicle populations) were isolated from 
the cultured supernatant of three melanoma cell lines. To rigor-
ously define the heterogenous EV population isolated, the vesicles 
were characterized by proteomic assesment, size distribution, 
FigUre 2 | hypoxia increases extracellular vesicles (eVs) production 
in metastatic melanoma cell line sKMel28 not primary melanocytes. 
Melanoma cell lines and adult primary melanocytes were cultured under 
hypoxia or normoxia conditions for 48 h. Morphology and CD63 vesicle 
marker expression of SKMEL28 EVs was confirmed by immune electron 
microscopy (a) and vesicle size distribution and particle concentration 
measured by nanoparticle tracking analysis (Nanosight) [(B), representative 
image]. Total concentration of normoxic (gray) or hypoxic (black) vesicles 
isolated from three melanoma cell lines and healthy primary melanocytes was 
quantified by Nanosight following three replicate 30-s video captures of three 
EV preparations (c) (n = 3 independent experiments). Statistical significance 
was determined by two-tailed t-test analysis (*p < 0.05).
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morphology and immunogold staining by EM. To ensure EV 
purity from other non-EV cellular compartments, transmem-
brane, lipid-bound, and cytosolic proteins enriched in EVs were 
quantified by mass spectrometry (Table S1 in Supplementary 
Material). Proteomic profiles of each of the EV preparations 
showed enrichment for six or more EV-associated proteins 
and had a single histone (SKMEL28, A375) or no intracellular 
proteins (C32TG) associated with non-EV compartments, dem-
onstrating high EV purity. To qualitatively assess morphology 
and expression of vesicle membrane marker CD63, EVs isolated 
from SKMEL28 melanoma cell line were visualized by immuno-
electron microscopy (Figure 2A).
To characterize the composition of exosome and microvesicle 
populations within the melanoma cell line EVs isolated, vesicle 
size distribution and total concentration were first quantified 
and compared to EVs isolated from adult primary melanocytes 
under normoxic and hypoxic conditions (Figures  2B,C). 
By nanoparticle tracking analysis (NTA), average vesicle size of 
hypoxic EVs did not vary significantly from EVs cultured under 
normal conditions for any of the EV sources analyzed (Table S2 
in Supplementary Material); however, vesicle production was 
found to be significantly increased in the melanoma cell line 
SKMEL28 under hypoxic compared to normal culture conditions 
(6.94 ×  1010 vs. 3.53 ×  1010 particles/mL, p =  0.03). Inversely, 
EV production was significantly decreased in primary non-
malignant melanocytes cultured under hypoxic stress compared 
to normal conditions (4.55 ×  1010 vs. 9.73 ×  1010 particles/mL, 
p =  0.03) (Figure  2C). This data suggests melanoma EVs can 
be generated under hypoxic conditions in vitro amenable to the 
hypoxic core observed in invading primary tumors in vivo.
Next, we sought to determine whether melanoma-derived 
EVs had the propensity to regulate DC maturation and the 
surrounding cytokine and chemokine milieu. Negatively 
isolated CD14+ monocytes from PBMCs of healthy human 
donors were cocultured to the DC fate in  vitro with CD40L 
in the presence or absence of SKMEL28-derived EVs or 
empty liposomes. To evaluate the sequential maturation of 
DCs, expression of Class I and II MHC complexes, maturation 
markers CD83 and CD86 and cytokine and chemokine profiles 
were defined. Phenotyping by flow cytometry, expression of 
Class I and Class II MHC molecules did not vary in response 
to EV treatment suggesting that initial antigen presentation 
is not likely affected by melanoma-derived EVs. Interestingly, 
expression of costimulatory markers CD83 and CD86 were 
significantly decreased in DCs treated with melanoma-derived 
EVs compared to either liposome-treated DCs or DCs alone 
(Figures  3A,B). Inhibition of costimulation was confirmed 
by imaging flow cytometry whereby fluorescently labeled 
melanoma EVs colocalized with DCs and correlated with 
decreased CD86 expression compared to DCs matured in the 
presence of CD40L alone (Figure  3C). Overall, these data 
demonstrate that melanoma EVs negatively regulate human 
monocyte maturation to the DC fate at the costimulatory stage 
of DC differentiation.
To define the surrounding milieu of the in  vitro EV-treated 
DCs, culture supernatants were collected on day 7 following 
FigUre 3 | Melanoma-derived extracellular vesicles (eVs) suppress dendritic cell (Dc) maturation in vitro. CD14+ human monocytes were matured to 
DC fate with CD40L in the absence or presence of SKMEL28 melanoma EVs, empty liposomes, or PBS. On day 7, phenotyping by flow cytometry evaluated DC 
expression of MHC molecules (HLA Class I, HLA-DR) and costimulatory molecules (CD83 and CD86) by histogram or the percent positive cells (mean ± SEM) 
(n = 8) (a,B). Representative image of reduced CD86 expression by imaging flow cytometry in DCs cocultured with fluorescently labeled melanoma EVs (n = 3) (c). 
Multiplex results of four analytes significantly decreased (Flt3L, IL-15, MIP-1α, and MIP-1β) in the presence of melanoma EVs compared to liposome-treated control 
(n = 5) (D). Cytokine and chemokine concentrations were reported in picogram per milliliter (mean ± SEM). Statistical significance was determined by two-tailed 
t-test analysis (*p < 0.05, **p < 0.01, p < 0.001). [EV-treated DCs are denoted by dotted line and dark gray shading on histograms for CD83 and CD86 expression 
in panel (a).]
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monocyte-derived DC maturation, and quantification of 38 
cytokines and chemokines was performed by multiplex analysis. 
From this panel, four chemokines were found to be differentially 
regulated by DCs cultured in the presence of melanoma-derived 
EVs compared to a liposome-treated controls (Figure  3D). 
Decreased levels of Th1-polarizing Flt3L and IL-15 chemokines 
and decreased levels of DC-recruiting chemokines (29), MIP-
1α and MIP-1β, were observed in the conditioned media of 
monocytes matured with melanoma EVs, suggesting in addition 
to compromising maturation, EV-conditioned DCs may elicit 
functional effects on immune cells downstream and modulate 
DC migration.
To elucidate the cargo present within melanoma-derived EVs, 
protein composition of the melanoma EVs was interrogated 
by mass spectrometry. Protein lysates of EVs yielded a shared 
proteomic signature of 21 proteins among all three melanoma 
cell lines assessed [Table 1(A)]. Strikingly, 11 of these 21 proteins 
had previously been identified as playing a functional role in 
TaBle 1 | Profiling of melanoma-derived extracellular vesicle (eV) protein cargo: Venn diagram summarizing the number of unique proteins identified 
in eVs isolated from 3 melanoma cell lines of which 21 proteins were shared among all 3 eV preparations (a); total peptide count of the 21 proteins 
identified in the shared signature and associated roles in dendritic cell (Dc) maturation (B).
(a) (B) Protein name Peptide count Functional role in 
dendritic cell (Dc) 
maturation
reference
sKMel28 c32Tg a375
S100A8 5 5 4 Inhibitory (30)
S100A9 3 5 3 Inhibitory (31)
Annexin A1 4 9 12 Inhibitory (32)
Annexin A2 23 26 10 Inhibitory (33)
Heat shock cognate 
protein 71 kDa
17 12 19 Activating (35)
Fibronectin 10 14 26 Activating (36)
Laminin subunit gamma 1 15 16 9 Activating (36)
Prolactin-inducible protein 2 6 3 Activating (37)
Procollagen-lysine 4 17 9 Activating (38)
ICAM1 6 4 4 Inhibitory/activating (34, 39)
Annexin A5 11 21 3 –
Chloride intracellular 
channel protein
2 4 3 –
Lysozyme C 3 4 3 –
Alpha enolase 2 22 15 –
Glyceraldehyde-3-
phosphate dehydrogenase
3 17 6 –
Glucose 6 phosphate 
isomerase
2 12 5 –
Glutathione S transferase 2 5 4 –
Fructose bisphosphate 
aldolase
9 16 7 –
Gelsolin 3 6 7 –
Tenascin 52 11 16 –
14-3-3 Protein zeta delta 6 12 4 –
TaBle 2 | Defining melanoma-derived eV rna cargo.
gene name gene 
abbreviation
Fold change 
(relative 
to primary 
melanocyte 
eV)
Secreted phosphoprotein 1 SPP1 6.29
Signal transducer and activator of 
transcription 1
STAT1 6.17
Toll-like receptor 4 TLR4 6.06
CD40 ligand CD40LG 5.24
Proto-oncogene c-Maf MAF 4.89
Toll-like receptor 6 TLR6 4.47
Polycomb group ring finger 2 PCGF2 3.96
Solute carrier family 11 member 1 SLC11A1 3.74
Growth factor independent 1 GFI1 3.64
Janus kinase 1 JAK1 3.61
Interleukin 9 IL9 3.56
Vascular endothelial growth factor A VEGFA 3.34
CCAAT/enhancer binding protein beta CEBPB 3.17
Interleukin 24 IL24 3.17
Fold regulation of significant (detection threshold ≥3-fold change) genes enriched 
by quantitative RT-PCR in SKMEL28 EVs relative to primary melanocyte EVs (n = 3 
independent experiments).
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DC maturation including inhibition of costimulation expres-
sion mediated by S100A8 (30), S100A9 (31), Annexin A1 (32), 
Annexin A2 (33), and ICAM1 (34) [Table 1(B)].
In addition to protein cargo, EVs have demonstrated the capac-
ity to transport nucleic acids. To evaluate if melanoma-derived 
EVs were enriched for immune-modulating mRNAs, 84 genes 
involved in generating downstream T helper cell-, Th1-, and 
Th2-specific responses were measured by qRT-PCR. Following 
amplification, 14 genes were found to be differentially increased 
in melanoma EVs relative to primary melanocyte EVs, each with 
defined T cell-polarizing effects (Table 2). These findings suggest 
melanoma-derived EVs are selectively enriched for cargo with the 
potential to modulate T cell polarization and DC differentiation.
To isolate the effects of individual and combined EV cargo 
in regulating this process, DC maturation was conducted in the 
presence of the EV-associated proteins with identified inhibi-
tory functions on DCs. In vitro, monocytes were matured to 
DCs with CD40L and coadministered recombinant proteins on 
day 5 specific to S100A8, S100A9, ICAM1, and AnnexinA1 
to determine whether DC maturation could be modulated by 
these proteins alone or in combination. Individually, S100A8 
and S100A9 proteins as well as all four inhibitory EV proteins 
combined significantly decreased CD83 expression in DCs 
compared to DCs matured with CD40L alone (Figure 4A). DC 
maturation was also assessed by CD86 expression, whereby DCs 
matured in the presence of all proteins combined resulted in 
decreased CD86 expression while S100A9 was the only protein 
able to decrease CD86 expression individually (Figure  4B). 
Taken together, these data suggest melanoma EV cargo, 
FigUre 4 | extracellular vesicles (eVs) cargo works synergistically to 
drive compromised dendritic cell (Dc) phenotype. Maturation of DCs 
was evaluated by CD83 expression (a) and CD86 expression (B) on day 7 
following coculture with recombinant proteins specific to EV protein cargo or 
all of the recombinant proteins administered in combination (all of the 
recombinant proteins combined). Statistical significance was determined by 
two-tailed t-test analysis (*p < 0.05, **p < 0.01, ***p < 0.001).
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DiscUssiOn
In this study, we examined the function of melanoma-derived EVs 
as proficient signaling complexes capable of compromising DC 
maturation and regulating cytokine and chemokines in the sur-
rounding milieu. Characterization of the proteomic and genomic 
cargo within melanoma EVs specifically identified four proteins 
with known immune-modulating functions, which in combina-
tion decreased DC maturation in  vitro. DC maturation was 
similarly assessed in the presence of individual EV cargo proteins 
demonstrating that S100A8 decreases expression of the costimula-
tory marker CD83 while coculture of DCs with S100A9 resulted in 
decreased expression of both CD83 and CD86 suggesting that EV 
cargo is responsible for mediating the immature DC phenotype. 
Finally, evidence of EVs within human afferent lymphatic channels 
provides the first correlative evidence in support of EVs trafficking 
from the primary tumor to draining SLNs in patients.
Serving dual functions by orchestrating antitumor immune 
responses and fostering the first site of metastasis, the SLN 
comprises a unique immunological environment to study early 
stages of melanoma progression. Angiogenic factors including 
VEGF, TGF-β, and TNF-α have been previously shown to play 
an active role in priming the lymphoid microenvironment 
for melanoma migration; however, the events responsible for 
inducing secretion of these factors are largely unknown (40). 
In patients, we previously demonstrated by IHC and flow 
cytometry studies that changes in basic immune cell subsets and 
polarization within the SLN precede evidence of nodal metas-
tasis including decreased CD8+ T cells, increased monocytes, 
and decreased expression of DC maturation marker CD86 (9, 
10). To appreciate a more comprehensive immune phenotype of 
SLNs at the resolution of single cells, our current study exam-
ined freshly isolated SLN immune profiles by mass cytometry 
(Figure 1). At the earliest stages of melanoma, a SLN clinically 
negative for metastatic spread compared to a healthy lymph 
node illustrated a conserved phenotype in agreement with these 
earlier studies suggesting that decreased expression of T-bet 
and decreased DC costimulatory marker CD80 are early steps 
in regional lymph node remodeling.
Historically, intercellular communication mechanisms 
responsible for mediating immune responses have focused on 
cell-to-cell and receptor–ligand mediated interactions (41) as 
well as soluble cytokines, chemokines, and angiogenic factors 
(42). Recently, EVs have emerged as novel mediators of intercel-
lular communication composed of both exosome (30–100 nm) 
and microvesicle (100  nm–1  μm) subpopulations. In addition 
to their size, exosomes are defined by their endosomal origin 
and microvesicles by their budding from the plasma membrane; 
however, exclusive cargo markers to differentiate these vesicles 
based on their downstream functions on the recipient cell are less 
clear. Here, we assessed the functional effects of melanoma EVs 
on DCs and therefore chose to evaluate a heterogeneous popula-
tion of both exosomes and microvesicles as we hypothesized both 
populations are abundant in  vivo and may work in tandem to 
modulate DC maturation.
Transporting signals from their parent cell to a target cell 
through cargo, numerous studies have extensively profiled the 
including established chronic inflammatory mediators S100A8 
and S100A9 have the capacity to drive EV inhibitory effects 
on DC maturation.
Finally, to consider the implications of this in vitro model in 
humans, we assessed afferent lymphatic channels draining into 
the identified, premetastatic SLN of patients for evidence of traf-
ficking EVs. Our initial analysis of afferent lymph fluid identified 
a novel source of lymphatic EVs. Size distribution of human lym-
phatic EVs was determined by NTA with an average vesicle size 
of 197.8 nm (Figure 5A), and electron micrographs collectively 
confirm the presence of vesicular structures within the lumen of 
the channel (Figure 5B) and strong CD63 expression on isolated 
lymphatic EVs (Figure 5C). To our knowledge, this is the first 
published evidence of EVs in human lymphatics.
FigUre 5 | characterization of novel human lymphatic extracellular vesicles (eVs). Electron micrographs confirm vesicle structures (inset, denoted by arrows) 
in the lumen of human afferent lymphatic channels (a) EVs isolated from lymphatic fluid entering SLN were visualized and quantified (black line) compared to methylene 
blue, channel tracer dye (gray line) alone by nanoparticle tracking analysis (B). Isolated lymphatic EVs express vesicle marker CD63 by immunogold labeling (c).
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proteomic and genomic cargo present in EVs obtained from 
various cell sources (43). From these studies, diverse immune 
regulatory functions of EVs have been defined including antigen 
presentation, NK cell activity and T cell activation (13). In  the 
cancer setting, increased tumor-derived EVs circulating in 
plasma have been proposed as potential biomarkers for disease 
progression (44). In vivo, Peinado et al. provided the first evidence 
to suggest that melanoma exosomes have prometastatic potential 
by educating bone marrow-derived progenitor cells in mice (45), 
while few studies have considered the mechanistic role of tumor-
derived EV cargo in driving functional effects on non-malignant 
cells. The stroma and target site of spread is likely just as critical to 
survival of the malignant cells as the metastatic cells themselves. 
In this study, we identified melanoma-derived EVs contain-
ing cargo enriched for immune regulatory proteins including 
S100A8, S100A9, Annexin A1, and ICAM1 (Table 1) and further 
demonstrated that all of the proteins as well as S100A8 or S100A9 
individually have the functional capacity to compromise DC 
maturation (Figure 4).
First described as potent antimicrobials secreted by neutro-
phils, S100A8 and S100A9 proteins form a stable heterodimer, 
calprotectin, with established immunogenic functions (46). 
Members of the larger S100 calcium-binding protein family, 
S100A8 and S100A9, regulate epithelial cell differentiation with 
increased expression of these proteins observed in inflammatory 
conditions and advanced stages of skin cancer (47). S100A8 
and S100A9, individually or as a heterodimeric complex, signal 
through cell surface receptors TLR4 and RAGE resulting in 
Myd88-mediated NF-kB activation downstream (47). In vivo 
murine studies conducted by Cheng et  al. demonstrated that 
overexpression of S100A9 inhibited DC and macrophage differ-
entiation and promoted MDSCs (31). In this study, we evaluated 
EV protein cargo for their capacity to regulate CD83 and CD86 
expression in DCs and observed that DCs cultured in the presence 
of S100A8 and S100A9 had impaired maturation. Interestingly, 
protein ligands S100A8 and S100A9 and cognate receptor TLR4 
were all identified in melanoma EV cargo. Future work is focused 
on elucidating if conserved signaling pathways are present within 
EV cargo and may further inform mechanisms responsible for 
modulating target cell fates.
To our knowledge, this is the first study examining the 
direct effects of melanoma-derived EV cargo on compromised 
DC maturation, a DC phenotype observed in pre-metastatic 
human SLNs. In addition, our preliminary evidence suggests 
that similar EVs are present within human lymphatics and ongo-
ing studies are exploring the immune-modulatory functions 
of these novel EVs on immune cell subsets. Taken together, 
this work suggests melanoma EVs, and their associated cargo 
11
Maus et al. Melanoma EVs Shape DC Fate
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 358
serve as modulators of DC maturation and cytokine/chemokine 
production in  vitro and should be further characterized in 
human lymphatics to assess a potential functional role for EVs 
in harboring a premetastatic SLN niche permissive for future 
tumor dissemination.
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